Nasdaq · Healthcare

Cytek Biosciences, Inc. (CTKB)

As-reported financials and recent SEC filings for Cytek Biosciences, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$201.5M

Net income

$-66.5M

Net margin

-33.0%

Diluted EPS

—

ROE

-19.5%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$201.5M	$200.5M	$193.0M	$164.0M	$128.0M
Gross profit	$104.5M	$111.1M	$109.4M	$101.0M	$79.1M
Operating income	$-40.4M	$-20.5M	$-27.8M	$-1.8M	$9.2M
Net income	$-66.5M	$-6.0M	$-12.1M	$2.5M	$3.0M
Diluted EPS	—	—	$-0.09	$0.02	$0.00

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

32026-06-30

8-K2026-06-25

42026-06-16

8-K2026-06-16

42026-06-12

42026-06-12

42026-06-12

42026-06-12

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on CTKB

Search Cytek Biosciences, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.